Physician profile
Jimmy D Huebert
NPI 1225050834
$3,245.87
in general payments reported to CMS, 2019-2025
13 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 96% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $44.41 · 2021: $21.76 · 2022: $916 · 2023: $272 · 2024: $424 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,092 · Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,092.39 |
| Food and Beverage | $1,032.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,040.86 | 2022-2025 | Proclaim, Ensite Precision, Eterna |
| Si-Bone, INC. | $937.27 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $51.35 | 2019-2021 | |
| Arteriocyte Medical Systems, INC. | $49.07 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $40.99 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $24.53 | 2025 | |
| Medline Industries Lp | $18.02 | 2023 | |
| Saluda Medical Americas, INC. | $16.00 | 2024 | Evoke |
| Bioventus LLC | $14.70 | 2025 | Xcell |
| Nevro Corp. | $14.67 | 2024 | Senza |
| Ferring Pharmaceuticals INC. | $13.48 | 2022 | |
| Avanos Medical | $12.93 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Orthogenrx INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Huebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.